Central Pain Syndrome Management Market Size, Share, and COVID-19 Impact Analysis By Drug Class (Antidepressants, Anticonvulsants, and Others), By Route of Administration (Oral, Intravenous, and Tropical), By Application (Neuropathic Pain, Musculoskeletal Pain, Epilepsy, Seizures, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

Central pain syndrome is a neurological disorder caused by the dysfunction or damage of the central nervous system (CNS), which includes the brain, brainstem, and spinal cord. This syndrome can be caused by stroke, tumors, multiple sclerosis, epilepsy, brain or spinal cord trauma, or Parkinson's disease. Pain medications often provide little or no relief for those affected by central pain syndrome. However, some antidepressants and anticonvulsants are useful in treating central pain syndrome.

An increase in the number of patients suffering from CNS diseases such as mental health and neurodegenerative diseases is the major factor contributing to the growth of the central pain syndrome management market.

• For instance, according to data published by World Health Organization, the prevalence of Parkinson's disease (PD) has doubled in the past 25 years with global estimates witnessing over 8.5 million individuals suffering from PD in 2019.

Furthermore, government and non-government entities are heavily investing in the development of therapeutics for the disease, which is expected to fuel the growth in the market.

• For instance, in July 2022, Vertex Pharmaceuticals Incorporated announced the initiation of Phase 3 clinical trial for selective NaV1.8 inhibitor VX-548 for acute and neuropathic pain.

However, adverse reactions associated with the drugs to treat central pain syndrome and the high research and development expenditure required for developing them are factors expected to hamper the growth of the market to a certain extent.

Impact of COVID-19 on the Central Pain Syndrome Management Market

The central pain syndrome management market faced a slightly negative impact in 2020 by the COVID-19 pandemic due to disruptions in supply chains and bio-manufacturing changes. Also, pharmaceutical companies operating in the central pain syndrome management market changed their R&D expenditure and workforce towards the development of COVID-19 therapeutics and vaccines. However, the market growth stabilized in 2021 owing to the reopening of manufacturing sites and the release of lockdown restrictions.

Key Insights

The report will cover the following key insights:

• Prevalence of Neurodegenerative Diseases - by Key Countries/Regions, 2021/2022.


• Pipeline Analysis, Key Players.


• Overall R&D Expenditures, Key Players, 2021.


• Overview of Regulatory Scenario - by Key Countries/Regions.


• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.).


• Impact of COVID-19 on the Market.

Analysis by Drug Class

Based on drug class, the antidepressants segment accounted for a significant proportion of the global central pain syndrome management market in 2022. The growth was mainly attributed to the constant innovation and the development of therapeutic drugs to treat disease indications.

• For instance, in June 2021, Sage Therapeutics, Inc. and Biogen, Inc. announced positive pivotal phase 3 results for Zuranolone, an investigational two-week, once-daily therapeutic being evaluated for major depressive disorder.

Furthermore, rising awareness regarding mental health in developing nations is estimated to drive segmental growth over the forecast period.

The anticonvulsants segment is projected to grow at a significant CAGR over the forecast period owing to the increasing awareness about the anticonvulsants available in the market and the patent expiration of many blockbuster drugs.

Regional Analysis

North America dominated the central pain syndrome management market in 2022 and is projected to maintain its position over the forecast period. The growth is mainly attributed to the constant growing geriatric population and the rising burden of central nervous system disease in the U.S.

• For instance, according to data published by Alzheimer's Association, around 6.5 million Americans age 65 and older are living with Alzheimer's in 2022. As the number of older Americans is growing rapidly the number of new and existing cases of Alzheimer's is projected to reach around 12.7 million by 2050.

In addition, the robust growth of technology in the healthcare sector and increasing product launches, coupled with the rising level of research and development are driving the growth of the market in North America.

In Asia Pacific, the market for central pain syndrome management is expected to grow at a significant rate over the forecast period. Factors such as a large patient base with high unmet medical needs, improving healthcare infrastructure in developing countries such as China and India, and increasing awareness regarding mental health are projected to drive treatment adoption rates during the forecast period.

Key Players Covered

The report will include the profiles of key players such as Sandoz, Amneal Pharmaceuticals, Inc., GlaxoSmithKline, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Xi'an Tian Guangyuan Biotech Co., Ltd., AdvaCare Pharma, Zydus Cadila Healthcare Ltd., Janssen Global Services, LLC, and others.

Segmentation

Key Industry Developments

• September 2021: AbbVie announced the U.S. Food and Drug Administration (FDA) approval of QULIPTA (atogepant) indicated for the preventive treatment of episodic migraine in adults.


• August 2020: ACADIA Pharmaceuticals, Inc. acquired CerSci Therapeutics with an aim to strengthen its product portfolio of novel compounds for neurological conditions.